Overview
Switzerland is a global life-sciences hub: Roche and Novartis (Basel), Lonza (Basel-Visp), Idorsia (Allschwil), Galderma (Lausanne), Sonova (Stäfa), Straumann (Basel). Median gross annual: CHF 110,000–160,000.
R&D (research and development)
- Junior scientist (fresh PhD): CHF 105,000–125,000
- Experienced scientist (3–7 yrs): CHF 125,000–160,000
- Senior scientist: CHF 160,000–210,000
- Principal scientist / Group leader: CHF 200,000–280,000
- Head of research: CHF 280,000–450,000+ + bonus + LTI
- Chief scientific officer (CSO): CHF 500,000–1,200,000+
Clinical operations
- Junior clinical research associate (CRA): CHF 90,000–110,000
- Senior CRA: CHF 115,000–145,000
- Clinical project manager: CHF 130,000–180,000
- Senior clinical project manager: CHF 170,000–230,000
- Head of clinical operations: CHF 250,000–400,000+
Regulatory affairs
- Junior regulatory affairs specialist: CHF 100,000–125,000
- Senior RA: CHF 130,000–175,000
- RA manager: CHF 175,000–230,000
- Head of regulatory affairs: CHF 230,000–350,000+
Production / quality (GMP)
- Production specialist: CHF 85,000–110,000
- Senior production manager: CHF 130,000–180,000
- Site head (Lonza, Roche site): CHF 250,000–450,000+
- Qualified Person (QP): CHF 140,000–220,000
- Senior quality control / QA: CHF 110,000–150,000
Biotech (Idorsia, Bachem, Moleac, Newron, ADC Therapeutics, Numab)
- Junior scientist: CHF 100,000–120,000
- Senior scientist: CHF 150,000–200,000
- VP R&D biotech: CHF 250,000–450,000+ + stock options
MedTech (Sonova, Straumann, Medtronic, Stryker, Roche Diagnostics)
- Junior R&D engineer: CHF 95,000–115,000
- Senior R&D engineer / project leader: CHF 130,000–180,000
- MedTech product manager: CHF 140,000–200,000
- R&D director: CHF 250,000–400,000+
Data / digital health
- Junior bioinformatician: CHF 100,000–125,000
- Senior data scientist (health): CHF 140,000–180,000
- Senior computational biologist: CHF 150,000–200,000
By employer
- Roche (Basel): top of market, +10–20%, excellent bonuses (15–30%), premium pension and training
- Novartis (Basel): Roche level, more matrix structure
- Lonza (Basel, Visp): global CDMO leader, solid salaries, rapid growth
- Idorsia, Galderma, Sonova: market level, stock options possible
- Biotechs and scale-ups: market salaries + equity
- Academia (EPFL, ETHZ, Friedrich Miescher Institute): –20–30% but prestige, scientific freedom
By region
- Basel / Basel-Country: European pharma capital, +5–10%
- Zurich: MedTech, biotech, +5%
- Lausanne / Vaud: EPFL spin-offs, Galderma, median
- Geneva: WHO, health NGOs, GAVI, median
Career tips
- A PhD is almost mandatory in senior R&D (+CHF 20,000–40,000)
- Pharma industry pays significantly more than academia
- Biotechs offer equity = potentially huge upside on IPO/acquisition
- Academia → industry transitions add 30–60% to salary
- Rare skills 2026: genetics, mRNA, bispecific antibodies, targeted oncology, AI in drug discovery